

LONG TERM QUALITY OF LIFE AFTER CHEMOTHERAPY AMONG NON-EPITHELIAL OVARIAN CANCER SURVIVORS

Pr Florence JOLY, MD, PhD.

INTRODUCTION / BACKGROUND

- **Germ cell (GCT)** and **sex cord stromal (SCST)** tumors:
 - are **rare cancers of the ovary**,
 - affect **young women**,
 - are associated with a **high survival rate**.
- Standard treatment consists in:
 - surgery (conservative)
 - **chemotherapy** (CT) [bleomycin, etoposide and cisplatin (**BEP**)], depending on the stage and the prognostic factors, as for testicular cancers.
- As reported in testicular cancer, CT may induce sequelae impacting quality of life (QoL)

INTRODUCTION / BACKGROUND

Not evaluated among GCT and SCST survivors



VIVROVAIRE TR study:

The French Rare Malignant Gynecological Tumors (TMRG)/GINECO case-control VIVROVAIRE Rare Tumors study assessed

Chronic fatigue, QoL and long-term side-effects

of CT among GCT and SCST survivors treated with BEP, as compared to age-matched healthy women (controls)

METHODS



⇒ **Group of interest: 144 GCTS & SCST**
≥ 2 years after treatment with surgery & chemotherapy (identified from the INCa French Network for TMRG)

⇒ **Healthy CONTROL group: 144 women**
without cancer age-matched to patients (± 2 years) issued from the 'Seintinelles' research platform

Self-administered questionnaires

- ✓ Fatigue (MFI-20¹)
- ✓ Quality of life (FACT-G²/FACT-O³)
- ✓ Neurotoxicity (FACT/GOG-NTX⁴)
- ✓ Cognition (FACT-Cog⁵)
- ✓ Day to day life (Living condition questionnaire)
- ✓ Anxiety /Depression (HADS⁶)
- ✓ Insomnia (ISI⁷)

¹MFI : Multidimensional Fatigue Inventory ; ²FACT-G: General Functional Assessment of Cancer Therapy; ³FACT-O: Functional Assessment of Chronic Therapy- Ovarian subscale, ⁴FACT/GOG-Ntx: Functional Assessment of Cancer Therapy/ Gynecologic Oncology Group–Neurotoxicity subscale; ⁵FACT-Cog: Functional Assessment of Cancer Therapy-Cognitive; ⁶HADS: Hospital Anxiety and Depression Scale, ⁷ISI: Insomnia Severity Index

Results : pts characteristics

Characteristics of 144 patients	P Value
Time since end of treatment Median in yrs	6.0 [3.5-9.3]
FIGO stages n (%)	
I / II	69 (48%)
III/IV	28 (27%)
unknown	37 (25%)
Histology n (%)	
Germ cell	92 (65%)
Sex cord stromal	
Granulosa	37 (26%)
Sertoli	6 (4%)
Other	9 (5%)
Initial chemotherapy	123 (85%)
Relapse chemotherapy	34 (24%)

Results – Patients / Controls issues


		nEOCS (n=144)	Controls (n=144)	P value
Age (years) mean (sd)		38.2 (13.7)	38.2 (13.6)	0.98
Fatigue (MFI)	General	41 (28%)	48 (33%)	0.44
	Physical	44 (31%)	42 (29%)	0.89
	Mental	31 (22%)	40 (28%)	0.27
Insomnia moderate and severe ISI		44 (31%)	32 (22%)	0.14
Quality of Life (FATC-G) Score*		81.0 (15.5)	80.1 (14.3)	0.60
Physical well-being mean(sd)*		23.3 (4.2)	24.0 (4.5)	0,13
Social well-being mean(sd)*		20.7 (5.5)	19.0 (4,9)	<0.01
Emotional well-being mean(sd)*		17.2 (4.2)	17.2 (5.2)	0.99
Functional well-being mean(sd)*		19.8 (5.2)	19.9 (4.7)	0.92
Ovarian cancer subscale mean(sd)*		33.0 (5.3)	34.9 (4.86)	<0,01
Emotional status (HADS)				
Anxiety		53 (37%)	47 (33%)	0.51
Depression		13 (9%)	13(9%)	1

* a lower score indicates a severe complaint or a severe symptom.

No difference between Pts and Controls

- ***Fatigue & Insomnia***
- ***General Quality of life***
- ***Anxiety & Depression***


More premature menopause and sexual difficulties



Results – Patients / Controls issues

Negative impact of health condition
on daily life

More Neurotoxicity and cognitive complaints



DISCUSSION-CONCLUSION

- **6 years after BEP** chemotherapy:
 - **Similar fatigue, global quality of life** between patients and controls
 - However, **more cognitive complaints & neuropathy** in patients vs controls
 - Higher risk of **premature menopause**
 - Negative **impact on sexual health**
 - Health conditions interfered more in their daily lives of patients than controls
- **Survival care plan** with long term follow-up should be proposed to patients to **anticipate these long term effects**

THANK YOU!



**23rd European Congress
on Gynaecological Oncology**
Oct 28-30, 2022 | Berlin, Germany

congress.esgo.org

The European Voice of Gynaecological Oncology

